Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2026-06-12 20:06:14 ET · period of report 2026-06-12 · accession 0001951287-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-12 20:06 | 2026-06-12 | SPRY | Karas Eric | Chief Commercial Off | M - OptEx | $1.50 | +25.0K | 37.2K | +205% | +$37.5K |
| DT | 2026-06-12 20:06 | 2026-06-12 | SPRY | Karas Eric | Chief Commercial Off | S - Sale+OE | $10.00 | -25.0K | 12.2K | -67% | -$250.0K |
| DT | 2026-06-12 20:06 | 2026-06-12 | SPRY | Karas Eric | Chief Commercial Off | M - OptEx | $0.00 | -25.0K | 519.6K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-12 | M | A | 25,000 | $1.50 | 37,176 | D | — | — | (F1) Includes 1,861 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2025. |
| 2 | Common | Common Stock | 2026-06-12 | S | D | 25,000 | $10.00 | 12,176 | D | — | — | (F2) The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-06-12 | M | D | 25,000 | $0.00 | 519,588 | D | $1.50 · — to 2032-05-23 | 25,000 Common Stock | (F3) Immediately exercisable. |